| HOME >> BIOLOGY >> TECHNOLOGY |
"To have a highly regarded selection committee realize the commercial potential for RVX-208 is important for us," stated Kenneth Lebioda, Senior Vice President of Business and Corporate Development at Resverlogix. "Atherosclerosis, the leading underlying cause of cardiovascular death, represents the largest cost center to health systems globally. Novel small molecules that enhance ApoA-I production have a diverse number of patient groups that they can help such as low HDL, acute coronary syndrome, diabetes, post myocardial infarction and Alzheimer's. A novel drug that could help these diseases will have a major positive impact on patients and health systems alike. This is where RVX-208 offers an unrivalled commercial opportunity for the life science industry," added Mr. Lebioda.
As a selected company, Resverlogix has been invited to present data on RVX-208 at Windhover's Therapeutic Area Partnerships conference on November 3-5, 2008 in Philadelphia.
About Windhover
Windhover Information Inc., an Elsevier company, has led the field in providing analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see http://www.windhover.com.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies f
'/>"/>
| SOURCE Resverlogix Corp. Copyright©2008 PR Newswire. All rights reserved |